Usage Examples
- The API comes from a site we have not audited since 2024, so it goes on the pre-approval inspection risk list.
- Our API Starting Material designation puts three synthetic steps outside Q7, and the reviewer already questioned it once.
- The supplier will only file a Type II DMF, so we need the letter of authorisation before the 3.2.S sections close.
What is Active Pharmaceutical Ingredient (API)?
Active Pharmaceutical Ingredient (API), also called the drug substance, is the component of a drug product intended to furnish pharmacological activity or other direct effect on the body. Every other component of the dosage form is an inactive ingredient.
The Active Pharmaceutical Ingredient exists as a distinct regulatory category because one material in a dosage form carries the therapeutic effect and most of the safety risk. FDA draws the line at 21 CFR 210.3(b)(7): an active ingredient is any component intended to furnish pharmacological activity or other direct effect on the body. Everything else in the formulation is an inactive ingredient.
The Active Pharmaceutical Ingredient's GMP scope starts at a point the company itself defines and documents. ICH Q7 applies from the moment the designated API Starting Material enters the process, and states plainly that it does not apply to steps prior to the introduction of that defined API Starting Material. ICH Q7 also stops immediately before sterile APIs are rendered sterile, and excludes vaccines, whole blood and plasma, plasma derivatives, and gene therapy APIs.
The Active Pharmaceutical Ingredient reaches a reviewer as CTD Module 3, section 3.2.S. ICH Q11 governs sections 3.2.S.2.2 through 3.2.S.2.6, where the applicant justifies the manufacturing process, the starting material selection, the drug substance critical quality attributes, and the control strategy. Where the API manufacturer will not disclose its process to the applicant, that information reaches FDA through a drug master file referenced with the holder's written authorisation.
Not to be confused with
- Drug product
- the drug product is the finished dosage form containing the API plus inactive ingredients (21 CFR 210.3(b)(4)); the API is one component inside it. An API certificate of analysis releases the API, never the drug product.
- Excipient
- an excipient is an inactive ingredient, defined at 21 CFR 210.3(b)(8) as any component other than an active ingredient. Excipients move through the same qualification and incoming-testing machinery as the API but carry none of the pharmacological effect.
- API Starting Material
- an API Starting Material is a raw material, intermediate, or API incorporated as a significant structural fragment into the API. It marks where ICH Q7 GMP begins; it is not the substance that gets registered as the drug substance.
- Intermediate
- an intermediate is a material produced during API processing that undergoes further molecular change or purification before it becomes an API. An intermediate sits inside the API's own process; it is not a separately registered substance.
The obligations split between the API manufacturer, the drug product manufacturer receiving it, and the applicant filing it.
What you must do
- 1Designate and document the rationale for the point at which API production begins, because ICH Q7 GMP applies from the introduction of the defined API Starting Material forward and not to any step before itICH Q7 §1.3
- 2Apply GMP of increasing stringency as the process advances from early API steps to final purification and packaging, and hold physical processing such as milling and micronising to at least the same standardICH Q7 §1.3
- 3Classify as an active ingredient any component intended to furnish pharmacological activity or other direct effect on the body; every remaining component of the formulation is an inactive ingredient21 CFR 210.3(b)(7)
- 4Test each incoming API lot for conformity with written specifications for purity, strength, and quality, or accept a supplier report of analysis only after running at least one specific identity test in house and validating the supplier's results at appropriate intervals21 CFR 211.84(d)(2)
- 5Provide the drug substance development and manufacturing information, including critical quality attributes and control strategy, in CTD Module 3 sections 3.2.S.2.2 through 3.2.S.2.6ICH Q11 §1
Common mistakes
Letting the supplier certificate of analysis stand in for incoming testing
21 CFR 211.84(d)(2) permits a supplier report of analysis only when the receiving manufacturer runs at least one specific identity test itself and validates the supplier's results at appropriate intervals. Drop either half and the exposure is every lot accepted since the last valid supplier qualification, not just the lot the investigator pulled.
Setting the API Starting Material too far downstream
Pushing the designated starting material late in the synthesis shrinks the GMP-controlled portion of the route and looks like a cost saving. ICH Q7 §1.3 requires a documented rationale for that point, and ICH Q11 makes starting material justification a reviewable part of 3.2.S.2.2 through 3.2.S.2.6. A rejected designation reopens the entire process description mid-review.
Assuming one Q7 supplier audit covers the whole chain
ICH Q7 stops immediately before a sterile API is rendered sterile and excludes vaccines, whole blood and plasma, plasma derivatives, and gene therapy APIs. The sterilisation, aseptic processing, and formulation steps fall under the finished-pharmaceutical CGMP regime instead, so a clean Q7 audit leaves those steps unassessed.
When This Matters
- The API comes from a site we have not audited since 2024, so it goes on the pre-approval inspection risk list.
- Our API Starting Material designation puts three synthetic steps outside Q7, and the reviewer already questioned it once.
- The supplier will only file a Type II DMF, so we need the letter of authorisation before the 3.2.S sections close.
Frequently Asked Questions
The API is the active substance itself; the drug product is the finished dosage form containing that API plus excipients. FDA defines drug product at 21 CFR 210.3(b)(4) as a finished dosage form such as a tablet or capsule, generally in association with inactive ingredients.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
